89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focusing on liver and cardiometabolic diseases, has announced the approval of Inducement Grants by its Compensation Committee. These grants, made under the company's 2023 Inducement Plan, include non-qualified stock options to purchase 265,000 shares of common stock, awarded to two new employees on October 10, 2024.
The Inducement Grants, aligned with Nasdaq Listing Rule 5635(c)(4), have an exercise price equal to the closing price of 89bio's common stock on the grant date. They will vest over four years, with 25% vesting after one year and the remainder in 12 equal quarterly installments, contingent on continued employment.
89bio, Inc. (Nasdaq: ETNB), una compagnia biofarmaceutica in fase clinica focalizzata su malattie epatiche e cardiometaboliche, ha annunciato l'approvazione dei Grant di Induzione da parte del suo Comitato per la Compensazione. Questi grant, effettuati ai sensi del Piano di Induzione 2023 dell'azienda, includono opzioni su azioni non qualificate per l'acquisto di 265.000 azioni ordinarie, assegnate a due nuovi dipendenti il 10 ottobre 2024.
I Grant di Induzione, in linea con la Regola di Quotazione Nasdaq 5635(c)(4), hanno un prezzo di esercizio pari al prezzo di chiusura delle azioni ordinarie di 89bio alla data di concessione. Essi matureranno in quattro anni, con il 25% che matura dopo un anno e il resto in 12 rate trimestrali uguali, a condizione di continuare l'impiego.
89bio, Inc. (Nasdaq: ETNB), una empresa biofarmaeutica en etapa clínica centrada en enfermedades hepáticas y cardiometabólicas, ha anunciado la aprobación de Subsidios de Inducción por parte de su Comité de Compensación. Estos subsidios, otorgados bajo el Plan de Inducción 2023 de la compañía, incluyen opciones sobre acciones no calificadas para comprar 265,000 acciones ordinarias, otorgadas a dos nuevos empleados el 10 de octubre de 2024.
Los Subsidios de Inducción, alineados con la Regla de Listado Nasdaq 5635(c)(4), tienen un precio de ejercicio igual al precio de cierre de las acciones ordinarias de 89bio en la fecha de concesión. Se devengarán durante cuatro años, con un 25% devengándose después de un año y el resto en 12 cuotas trimestrales iguales, sujeto a la continuación del empleo.
89bio, Inc. (Nasdaq: ETNB), 간질병 및 심혈관 대사 질환에 주력하는 임상 단계의 생명공학 회사는 보상위원회에 의해 유인 보상의 승인을 발표했습니다. 이 보상은 회사의 2023년 유인 계획에 따라 이루어졌으며, 2024년 10월 10일 두 명의 신입 직원에게 265,000주를 구매할 수 있는 비자격 주식 옵션을 포함합니다.
유인 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 주어지며, 행사가격은 부여일에 89bio의 보통주 종가와 같습니다. 이들은 4년에 걸쳐 확정됩니다, 1년 후에 25%가 확정되며, 나머지는 계속 고용되는 조건에 따라 12개의 동일한 분기별 할부로 지급됩니다.
89bio, Inc. (Nasdaq: ETNB), une entreprise bio-pharmaceutique en phase clinique axée sur les maladies hépatiques et cardiométaboliques, a annoncé l'approbation des subventions d'incitation par son Comité de Compensation. Ces subventions, effectuées dans le cadre du Plan d'Incinération 2023 de l'entreprise, incluent des options d'achat d'actions non qualifiées pour l'achat de 265 000 actions ordinaires, accordées à deux nouveaux employés le 10 octobre 2024.
Les subventions d'incitation, conformes à la Règle de Cotation Nasdaq 5635(c)(4), ont un prix d'exercice égal au prix de clôture des actions ordinaires de 89bio à la date d'attribution. Celles-ci s'accompliront sur quatre ans, avec 25 % devenant valables après un an et le reste en 12 versements trimestriels égaux, sous réserve de la poursuite de l'emploi.
89bio, Inc. (Nasdaq: ETNB), ein auf klinische Phase spezialisiertes biopharmazeutisches Unternehmen, das sich auf Leber- und kardiometabolische Erkrankungen konzentriert, hat die Genehmigung von Induktionszuschüssen durch seinen Vergütungsausschuss bekannt gegeben. Diese Zuschüsse, die im Rahmen des Induktionsplans 2023 des Unternehmens gewährt wurden, beinhalten nicht qualifizierte Aktienoptionen zum Kauf von 265.000 Stammaktien, die am 10. Oktober 2024 an zwei neue Mitarbeiter vergeben werden.
Die Induktionszuschüsse entsprechen der Nasdaq-Listing-Regel 5635(c)(4) und haben einen Ausübungspreis, der dem Schlusskurs der Stammaktien von 89bio am Tag der Gewährung entspricht. Sie reifen über einen Zeitraum von vier Jahren, wobei 25 % nach einem Jahr fällig werden und der Rest in 12 gleichen vierteljährlichen Raten, unter der Bedingung einer fortgesetzten Beschäftigung.
- Attraction of new talent with stock options as incentives
- Alignment of employee interests with company performance through equity grants
- Potential dilution of existing shareholders' equity
SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 265,000 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on October 10, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 studies for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
What are the details of 89bio's (ETNB) Inducement Grants announced on October 11, 2024?
How do the Inducement Grants align with Nasdaq rules for 89bio (ETNB)?
What is the exercise price for the stock options granted by 89bio (ETNB) on October 10, 2024?
How many new employees received Inducement Grants from 89bio (ETNB) as announced on October 11, 2024?
